10% Free customization
The global genomic cancer panel and profiling market is expected to reach $26.59 billion by 2033 from $9.90 billion in 2022. The global genomic cancer panel and profiling market is expected to grow at a robust rate of 9.43% during the forecast period 2023-2033. This growth is driven by advancements in genomic research and an increasing focus on precision medicine within the field of oncology. This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Introduction to Genomic Cancer Panel and Profiling
Genomic cancer panels and profiling represent a modern approach to detecting cancer by studying the genetic details of tumors before symptoms appear. The significant advantages of employing these panels lie in their ability to provide comprehensive genetic insights, facilitating early detection and the formulation of personalized treatment plans. The genomic cancer panel and profiling market is on the rise due to the transformative potential these technologies hold in reshaping cancer management. By enhancing the understanding of cancer genetics, these panels offer a more precise means of identifying specific genetic alterations, enabling healthcare professionals to tailor interventions accordingly.The global genomic cancer panel and profiling market has significant growth, attributed to the increasing demand for early cancer detection while treating cancer patients. The increasing popularity and appreciation of liquid biopsy tests have also played a critical role in the market growth. Furthermore, the increased cancer risk due to the changing lifestyle of people is also influencing the market growth.
Impact
The genomic cancer panel and profiling market has made an impact in the following ways:
- Personalized Treatment:
- Finding Cancer Early:
- Helping Doctors Choose Treatments:
- Research and Testing New Treatments:
- Clinical Trials and Research:
- Prognostic Information:
- Cost-Efficiency:
Market Segmentation:
Segmentation 1: by Tissue Testing
- Solid Tissue Testing
- Liquid Tissue Testing
Segmentation 2: by Cancer Panel Type
- Single-Gene Panel
- Multi-Gene Panel
Segmentation 3: by Cancer Type
- Lung Cancer
- Breast Cancer
- Colon Cancer
- Prostate Cancer
- Other Cancers
Segmentation 4: by Application
- Clinical
- Research
Segmentation 5: by Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In-Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Others
Segmentation 6: by End User
- Hospitals
- Clinical and Diagnostic Laboratories
- Research and Academic Institutes
- Other End Users
Segmentation 7: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Rest-of-the-World
Recent Developments in the Global Genomic Cancer Panel and Profiling Market
- In April 2023, Agilent Technologies, Inc. introduced the NGS assay, SureSelect Cancer CGP, to advance precision oncology through comprehensive genomic profiling (CGP). This assay expands the range of biomarkers available for solid tumor profiling with a rapid and highly efficient workflow.
- In January 2023, FOUNDATION MEDICINE, INC. (F. Hoffmann-La Roche Ltd) got FDA approval for its FoundationOne Liquid CDx test as a companion diagnostic for Rozlytrek. This test is relevant for ROS1+NSCLC patients and NTRK fusion-positive solid tumors patients.
- In October 2023, Invitae Corporation. received FDA market authorization for its Common Hereditary Cancers Panel. This achievement marks the first FDA-approved broad panel designed to detect germline variants linked to hereditary cancers.
- In February 2023, Exact Sciences Corp. introduced the OncoExTra therapy selection test in the U.S. OncoExTra is an advanced next-generation sequencing (NGS) genomic test that encompasses both DNA and RNA analysis, offering a comprehensive molecular profile of the patient's cancer. This test furnishes precise and actionable personalized results for doctors and their patients.
- In January 2023, F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.), in partnership with Natera, Inc., launched a FoundationOne Tracker early access program for clinical use, which is a personalized circulating tumor DNA (ctDNA) monitoring assay. The test investigational use version is now available for clinical trials.
- In April 2023, Agilent and Theragen Bio successfully partnered to advance bioinformatic solutions for cancer genomic profiling in South Korea. This collaboration integrated Agilent's SureSelect Cancer CGP assay with Theragen Bio's localized analysis software, leading to a transformation in translational research and a substantial boost in precision oncology within the region.
- In July 2023, Illumina Inc. and Pillar Biosciences Inc. formed a strategic partnership to offer Pillar's oncology assays worldwide as part of Illumina's oncology products. This collaboration provides advanced next-generation sequencing solutions, improving the efficiency and cost-effectiveness of oncology testing for personalized cancer treatment.
- In January 2022, Thermo Fisher Scientific, Inc. made an agreement with Oncocyte Corporation for the distribution of Thermo Fisher Scientific, Inc.'s two IVD assays on Thermo Fisher Scientific's Ion Torrent Genexus System. Oncocyte Corporation will also validate the company's Oncomine Comprehensive assay plus on the Genexus system.
Demand - Drivers, Restraints, and Opportunities
Market Driver:
Rising Need for Cancer Profiling in Developed Countries Drives Demand for Genomic Panels and Profiling Tests: Developed countries often have aging populations, where a larger proportion of individuals are in the elderly age group. Cancer incidence tends to increase with age, and as the population ages, the overall burden of cancer rises. This demographic trend drives a steady demand for cancer treatment and related healthcare services. Genomic cancer panels contribute to this by helping identify genetic markers associated with early-stage cancers. Early detection allows for timely and targeted interventions, potentially improving treatment outcomes and reducing the overall burden of the disease.Market Restraint:
Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market: Reimbursement reductions in the genomic cancer panel and profiling market have significant implications for both healthcare providers and patients. These reductions often lead to reduced financial support for these valuable diagnostic tests. As a result, healthcare providers may face challenges in offering these tests to patients, potentially limiting their accessibility.Market Opportunity:
Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis: Genomic cancer panel and profiling tests are an emerging field in health technology that has the potential to disrupt the traditional models of cancer screening. With these tests, a single and non-invasive blood test can assess multiple cancer types at once, with the help of which more cancer can be detected at an earlier stage when accompanied by screening programs. The technology is still in its developmental stage, and there are numerous tests presently under development with self-funded research. Additionally, very few of these tests are FDA-approved, and most of them are being prescribed as laboratory-developed tests that do not require FDA approvals.How can this report add value to an organization?
Product/Innovation Strategy: The global genomic cancer panel and profiling market has been extensively segmented based on various categories, such as tissue testing, cancer panel type, cancer type, application, technology, end user, and region. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.Methodology
Key Considerations and Assumptions in Market Engineering and Validation
- Detailed secondary research was performed to ensure maximum coverage of manufacturers/suppliers operational in a country.
- Exact revenue information, up to a certain extent, was extracted for each company from secondary sources and databases. The revenues related to the product and end user were estimated for each market player based on fact-based proxy indicators as well as primary inputs.
- The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of genomic cancer panels and profiling.
- The market contribution of the genomic cancer panel and profiling anticipates the launch of products in the future, which has been calculated based on historical analysis. This analysis has been supported by proxy factors such as the innovation scale of the companies, the status of funding, collaborations, customer base, and patent scenario.
- The scope of availability of genomic cancer panels and profiling in a particular region has been assessed based on a comprehensive analysis of companies’ prospects, the regional end-user perception, and other factors impacting the launch of products in that region.
- The base year considered for the calculation of the market size is 2022. A historical year analysis has been done for the period FY2018-FY2021. The market size has been estimated for FY2022 and projected for the period FY2023-FY2033.
- Revenues of the companies have been referenced from their annual reports for FY2021 and FY2022. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, product approval status, market collaborations, and operational history.
- Regional distribution of the market revenue has been estimated based on the companies in each region and the adoption rate of advance dental and robotics solutions. All the numbers have been adjusted to a single digit after the decimal for better presentation in the report. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the period 2023-2033.
- The market has been mapped based on the available genomic cancer panel and profiling. All the key companies with significant offerings in this field have been considered and profiled in this report.
- Market strategies and developments of key players have been considered for the calculation of the potential of the market in the forecast period.
Primary Research:
The primary sources involve industry experts in the global genomic cancer panel and profiling market, including the market players offering genomic cancer panels and profiling. Resources such as COOs, vice presidents, product managers, directors, and territory managers have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.The key data points taken from the primary sources include:
- Validation and triangulation of all the numbers and graphs
- Validation of the report’s segmentation and key qualitative findings for advance dental and robotics solutions
- Understanding the competitive landscape and business model
- Current and proposed production values of a product by market players
- Validation of the numbers of the different segments of the market in focus
- Percentage split of individual markets for regional analysis
Secondary Research
Open Sources
- Centers for Disease Control and Prevention (CDC), American Dental Association (ADA), World Health Organization (WHO), and National Center for Biotechnology Information, among others
- Annual reports, SEC filings, and investor presentations of the leading market players
- Company websites and detailed study of their portfolios
- Gold standard magazines, journals, whitepapers, press releases, and news articles
- Databases
The key data points taken from the secondary sources include:
- Segmentation and percentage share estimates
- Company and country understanding and data for market value estimation
- Key industries/market trends
- Developments among top players
- Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
- Quantitative data for mathematical and statistical calculations
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.Some prominent names in this market are:
- Agilent Technologies, Inc.
- ARUP Laboratories
- Burning Rock DX
- Caris Life Sciences
- Thermo Fisher Scientific, Inc.
- Danaher Corporation (Integrated DNA Technologies, Inc.)
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Fulgent Genetics
- Genecast Biotechnology Co., Ltd
- Illumina, Inc.
- Invitae Corporation
This product will be delivered within 3-5 business days.
Table of Contents
1 Markets
2 Industry Analysis
3 Market Dynamics
4 Competitive Insights
5 By Tissue Testing
6 By Cancer Panel Type
7 By Cancer Type
8 By Application
9 By Technology
10 By End User
11 By Region
12 Company Profiles
List of Figures
List of Tables
Executive Summary
The global genomic cancer panel and profiling market is estimated to reach $26.59 billion by 2033, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 9.43% during the forecast period 2023-2033.The global genomic cancer panel and profiling market has significant growth, attributed to the increasing demand for early cancer detection while treating cancer patients. The increasing popularity and appreciation of liquid biopsy tests have also played a critical role in the market growth. Furthermore, the increased cancer risk due to the changing lifestyle of people is also influencing the market growth.
USP of the Report
- Key trends
- Regulatory framework
- Market dynamics, including drivers, restraints, and opportunities
- Region and country-level analysis, including market size and forecast
- Cross-segmentation at the region level
- Detailed segmentation
Analyst Perspective
According to Swati Sood, Principal Analyst, 'Global genomic cancer panel and profiling market is a rapidly emerging market and is expected to revolutionize the field of oncology field in the coming years due to the continuous increase in the demand for cancer diagnosis and industrial analysis.'Key Companies Profiled
The key players profiled in the report include Agilent Technologies, Inc., ARUP Laboratories, Burning Rock DX, Caris Life Sciences, Thermo Fisher Scientific, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fulgent Genetics, Genecast Biotechnology Co., Ltd, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings., Paragon Genomics, and TempusKey Questions Answered in the Report
- How is the genomic cancer panel and profiling market revolutionizing cancer detection, treatment, and other applications landscapes?
- What are the major market drivers, challenges, and opportunities in the global genomic cancer panel and profiling market?
- What are the underlying structures resulting in the emerging trends within the global genomic cancer panel and profiling market?
- How did the COVID-19 pandemic impact the global genomic cancer panel and profiling market?
- What are the key development strategies that are being implemented by major players to sustain themselves in the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of genomic cancer panels and profiling products?
- What are the potential entry barriers that companies willing to enter a particular region in the market are expected to face?
- What will be the growth rate of the global genomic cancer panel and profiling market during the forecast period?
- How is each segment of the market expected to grow during the forecast period 2023-2033, and what revenue is anticipated to be generated by each of the segments?
- What are the growth opportunities for the genomic cancer panel and profiling companies in the region of their operation?
- Who are the leading players with significant offerings in the global genomic cancer panel and profiling market?
- Which companies are anticipated to be highly disruptive in the future and why?
Companies Mentioned
- Agilent Technologies, Inc.
- ARUP Laboratories
- Burning Rock DX
- Caris Life Sciences
- Danaher Corporation (Integrated DNA Technologies, Inc.)
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Fulgent Genetics
- Genecast Biotechnology Co., Ltd
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings.
- Paragon Genomics
- Tempus
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 198 |
| Published | December 2023 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 10.8 Billion |
| Forecasted Market Value ( USD | $ 26.59 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
